Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2423-2431

  Ha, Nghiem B ^a,c   Ha, Nghi B ^a   Garcia, Ruel T ^a,b   Trinh, Huy N ^a,b   Chaung, Kevin T ^a   Nguyen, Huy A ^b   Nguyen, Khanh K ^b   Levitt, Brian S ^b   Nguyen, Mindie H ^c  

^a Pacific Health Foundation   (United States)

^b San Jose Gastroenterology   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adefovir dipivoxil; Entecavir; HBeAg negative; Nonadherence; Outcome

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; COMMUNITY HEALTH SERVICES; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79960939356     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1610-5     Document Type: Article

References (32)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745. (Pubitemid 27527771)
2. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology. 2004;39:857-861. (Pubitemid 38337668)
3. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25:3-8. (Pubitemid 41254588)
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107. (Pubitemid 38365759)
5. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
7. Dai CY, Chuang WL, Hsieh MY, et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151.
8. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309-1319. (Pubitemid 36667310)
9. Heathcote EJ. Treatment of hepatitis B: the next five years. Clin Med. 2007;7:472-477. (Pubitemid 350043180)
10. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health. 2003;6:566-573. (Pubitemid 37187719)
11. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880-2883. (Pubitemid 35425074)
12. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. (Pubitemid 47171942)
13. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008;134:405-415. (Pubitemid 351181309)
14. Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol. 2011;54:6-8.
15. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292-297. (Pubitemid 36929407)
16. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. (Pubitemid 39129351)
17. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020. (Pubitemid 43357805)
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-1751. (Pubitemid 44958517)
19. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-1514.
20. Ha NB, Garcia RT, Trinh HN, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727-734.
21. Kravitz RL, Hays RD, Sherbourne CD, et al. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med. 1993;153:1869-1878. (Pubitemid 23329841)
22. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: A meta-analysis. Med Care. 2002;40:794-811.
23. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34:703-709. (Pubitemid 30395767)
24. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
25. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Discrepancy between virological breakthrough and confirmed genotypic resistance in chronic hepatitis B patients receiving nucleos(t)ide analogue therapy in clinical practice. Gastroenterology. 2010;138:S793 [abstract].
26. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.
27. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386. (Pubitemid 26261515)
28. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care. 1998;36:1138-1161. (Pubitemid 128456406)
29. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: A meta-analysis. Med Care. 2007;45:521-528.
30. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30:S171-S176. (Pubitemid 32268984)
31. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54:12-18.
32. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001;33:865-872. (Pubitemid 32831844)